On October 6, Revolution Medicines, Inc. fell 5.23% in regular trading, trading at $196.54/share, with Turnover of $44.4953 million.
The decline comes as the broader biotechnology sector experienced broad-based selling pressure, with peers Vaxcyte down 10.97%, Moderna down 6.1%, Natera down 5.27%, Twist Bioscience down 4.28%, and Amgen down 0.95%.
Revolution Medicines is a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, with advanced structure-based drug discovery capabilities and a deep pipeline targeting key signaling nodes in the RAS pathway.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)